Home » Newsletters » BioWorld Science

BioWorld Science

April 25, 2008

View Archived Issues

VCH-759 resistance mutations identified

PharmaGap reports results from animal studies of PhG-alpha1 for cancer

Lorus Therapeutics recaps Q3 highlights

AFM-13 acts according to expectations in preclinical studies

Pim kinase inhibitor SGI-1776 induces apoptosis in cancer cells

Monoclonal antibody against AMIGO-2 inhibits pancreatic tumor growth in vivo

La Jolla presents positive 12-month interim antibody data from phase III trial

Micromet enrolls first patient in a phase I BiTE antibody MT-110 trial

Oral PBI-1402 shows significant activity in chemotherapy-induced anemia

Pharming commences clinical program for Prodarsan in ageing diseases

FDA approves Vyvanse to treat adult ADHD

NovaRx's cancer vaccine enters phase III evaluation for NSCLC

Johnson & Johnson's SGLT2 inhibitor JNJ-28431754 to be evaluated in phase II studies

Lpath initiates dosing in phase I clinical trial of Asonep for cancer

Epeius presents results from phase I/II clinical trial of Rexin-G for pancreatic cancer

Sygnis receives E.U. orphan drug designation for AX-200 in ALS

Recent Tibotec patent reports novel anti-HIV agents

New anxiolytic and antidepressant agents disclosed in recent patent literature

Alpharma to withdraw and resubmit NDA to the FDA for Embeda

CHMP issues positive opinion for Medigene's rosacea drug Oracea

CHMP issues positive opinion for Neupro for restless legs syndrome

CHMP issues positive opinion for ranolazine for treatment of chronic angina

Recent patents describe novel therapeutic agents for neurological disorders

FDA approves Relistor for opioid-induced constipation

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...